Heart BMJ

AUGUST 26, 2024

Background Cardiac magnetic resonance (CMR) allows comprehensive myocardial tissue characterisation, revealing areas of myocardial inflammation or fibrosis that may predispose to ventricular arrhythmias (VAs). Conclusion CMR is a valuable tool in the diagnostic and prognostic evaluation of patients with VAs.

Arrhythmia 96

Arrhythmia Cardiomyopathy Heart Disease Tachycardia 96

Cardiomatics

APRIL 5, 2024

By understanding the nuances of abnormalities detected in Cardiomatics and interpreting detailed reports, healthcare professionals can intervene promptly to prevent adverse outcomes. Other times, an irregular recording can signal a medical emergency, such as a myocardial infarction or a dangerous arrhythmia.

Arrhythmia 92

Arrhythmia Tachycardia Bradycardia Electrocardiogram 92

Circulation: Cardiovascular Interventions

MARCH 9, 2025

However, the impact of nickel hypersensitivity on post-procedural outcomes remains poorly understood. No significant differences were observed in documented arrhythmias, bleeding, or stroke. These findings highlight the need for further research to optimize device selection and improve outcomes in nickel-hypersensitive patients.

Chest Pain 70

Chest Pain Cardiovascular Interventions Document Arrhythmia 70

Frontiers in Cardiovascular Medicine

APRIL 24, 2025

GLP-1 RAs have been used for diabetes and found to improve CV outcomes in diabetic and nondiabetic patients. IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits. They are authorized for treating obesity.

Blood Pressure 52

Blood Pressure Diabetes Obesity Risk Factors 52

Science Daily - Heart Disease

APRIL 26, 2024

However, the risk of arrhythmias following this procedure is reportedly high. The highly positive outcomes observed in primate models highlight the potential of this strategy. Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function.

Transplant 130

Transplant Arrhythmia Research Outcomes 130

Journal of Cardiovascular Electrophysiology

NOVEMBER 29, 2023

However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. About one-third of patients implanted with an LVAD will experience sustained VAs, predisposing these patients to worse outcomes and complicating patient management.

Arrhythmia 75

Arrhythmia Heart Failure Ablation Outcomes 75

HeartRhythm

MARCH 31, 2025

Aortic stenosis (AS) is a common valvular disease associated with significant morbidity, often complicated by arrhythmias that worsen outcomes. However, the arrhythmia prevalence and outcomes in hospitalized AS patients remain underexplored.

40

40

Open Heart

MARCH 22, 2025

Introduction Atrial fibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months.

Atrial Fibrillation 52

Atrial Fibrillation Exercise Quality of Life Document 52

HeartRhythm

APRIL 30, 2024

arrhythmias are common in pregnant women. However, data of clinical signs, course of pregnancy, obstetric and neonatal outcomes is limited.

Arrhythmia 40

Arrhythmia Outcomes 40

HeartRhythm

MARCH 31, 2025

Conventional therapies often fail to terminate VF/VT in electrical storms and are associated with worse outcomes. Stellate Ganglion Blockade (SGB) has emerged as an adjuvant option for refractory arrhythmias.

40

40

HeartRhythm

MARCH 31, 2025

Acute decompensated heart failure (ADHF) is common in hospitalized patients, with cardiac amyloidosis being a challenging subset due to protein deposition creating a unique substrate for arrhythmias. Data on the prevalence and outcomes of arrhythmias in ADHF with cardiac amyloidosis is limited.

40

40

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. Multivariate Cox regression analysis suggested that multifocal ablation (HR: 3.055, 95% CI: 1.4766.323) and NT-proBNP (per standard deviation, HR: 1.367, 95% CI: 1.1571.614) were independently associated with arrhythmia recurrence after ablation.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

Frontiers in Cardiovascular Medicine

OCTOBER 9, 2024

The primary outcome was ventricular arrhythmias, the secondary outcomes were bradycardia and atrial fibrillation (AF).ResultsOur Perioperative or postoperative use of DEX reduced the incidence of in-hospital ventricular arrhythmias [Odds Ratio (OR) 0.14, 95% Confidence Interval (CI) 0.03–0.66],

Arrhythmia 52

Arrhythmia Bradycardia Atrial Fibrillation Hospital 52

American College of Cardiology

FEBRUARY 19, 2025

In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.

Arrhythmia 54

Arrhythmia Cardiomyopathy Ablation AFIB 54

HeartRhythm

MARCH 31, 2025

IV lidocaine is used to treat refractory ventricular arrhythmia (VA). There is little data describing clinical outcomes of patients with HF, AF, and VA receiving lidocaine. Rapid lidocaine administration can cause dose-dependent reductions in ventricular contractility, arterial pressure, and heart rate (HR).

40

40

HeartRhythm

APRIL 30, 2024

Arrhythmias are common in patients with hypertrophic cardiomyopathy (HCM) and are associated with increased morbidity and mortality. Ventricular arrhythmias (VA) are less common compared to supraventricular arrhythmias yet are associated with worse outcomes in this patient population.

Arrhythmia 40

Arrhythmia Cardiomyopathy Ablation Outcomes 40

HeartRhythm

APRIL 30, 2024

Stereotactic arrhythmia radioablation (STAR) is used as a rescue treatment for refractory ventricular tachycardia (VT) following unsuccessful radiofrequency catheter ablation (RFCA). The mid-term outcomes of STAR, however, remain poorly known.

Tachycardia 40

Tachycardia Arrhythmia Outcomes Ablation 40

HeartRhythm

AUGUST 13, 2024

Atrial arrhythmias (AA), particularly atrial fibrillation (AF), are prevalent in CA and may impact long-term cardiovascular outcomes, prompting an investigation into early rhythm management strategies.2 1 Recent advancements in imaging and therapeutic agents have sparked considerable interest in this field.

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation Outcomes 40

HeartRhythm

MARCH 31, 2025

Arrhythmias in pediatric heart transplant patients have historically raised concerns for acute rejection, often prompting invasive evaluations and empiric treatment. Despite this, the association of post-transplant arrhythmias with adverse outcomes remains understudied.

40

40

HeartRhythm

APRIL 30, 2024

Ventricular tachycardia (VT) ablation in structural heart disease improves arrhythmia free survival. Procedural factors that influence these outcomes are not well described.

Arrhythmia 40

Arrhythmia Ablation Electrophysiology Outcomes 40

Open Heart

SEPTEMBER 28, 2022

Objectives Examine the association between arrhythmias and adverse maternal outcomes in women with structurally normal hearts. Arrhythmia was previously diagnosed in 58.0% After adjusting for age, parity and comorbidities, the presence of any arrhythmia was an independent predictor of CS (OR 1.7 AF and 8.1% 95% CI 1.2

Arrhythmia 52

Arrhythmia Tachycardia Atrial Fibrillation Outcomes 52

American College of Cardiology

FEBRUARY 20, 2024

What are the outcomes of the stellate ganglion block (SGB) with respect to recurrence of ventricular tachycardia/ventricular fibrillation (VT/VF)?

Arrhythmia 66

Arrhythmia Tachycardia Outcomes Article 66

HeartRhythm

MARCH 31, 2025

Adults with congenital heart disease (ACHD) are at increased risk for ventricular arrhythmias due to structural abnormalities. Catheter ablation (CA) is a key therapeutic option, but its complications in this population remain underexplored.

40

40

HeartRhythm

OCTOBER 7, 2024

Arrhythmias can lead to cardiac arrest (CA) and heart failure. When intractable, heart transplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.

Heart Transplant 40

Heart Transplant Transplant Arrhythmia Cardiac Arrest 40

HeartRhythm

MARCH 31, 2025

Hypertrophic cardiomyopathy is associated with arrhythmia and sudden cardiac death (SCD). Data remains sparse on the role of the utility of Implantable Loop recorders and impact on outcomes in HCM.

40

40

HeartRhythm

MARCH 31, 2025

Arrhythmias are common complications of acute coronary syndromes (ACS) and are associated with worse clinical outcomes and increased healthcare utilization. Despite their critical impact, the prevalence and outcomes of arrhythmias in ACS remain underexplored.

40

40

HeartRhythm

APRIL 30, 2024

The overall prevalence of arrhythmias in pregnancy is estimated at 68-166 per 100,000 pregnancy-related admissions. Arrhythmias in pregnancy are thought to be multifactorial in nature due to a combination of hemodynamic, hormonal and autonomic changes that occur during pregnancy.

Arrhythmia 40

Arrhythmia Outcomes 40

HeartRhythm

MARCH 31, 2025

Although cardiac magnetic resonance (CMR) can inform prognosis in ischemic cardiomyopathy, the recent PROFID CMR study did not identify optimal scar parameters for prediction of ventricular arrhythmia (VA) events.

40

40

HeartRhythm

MARCH 31, 2025

Cardiomyopathy (CM) is associated with arrhythmias, resulting in considerable morbidity and mortality. Atrial fibrillation (AF) is a common arrhythmia linked to adverse outcomes, yet mortality trends between AF and other arrhythmias (OA) in patients with CM remain understudied.

40

40

HeartRhythm

MARCH 31, 2025

The burden and impact of cardiac arrhythmias in patients hospitalized with diabetic ketoacidosis (DKA) remain poorly characterized despite the known cardiovascular complications of diabetes. Understanding these associations is crucial for risk stratification and management.

40

40

HeartRhythm

MARCH 31, 2025

Repeat catheter ablation is frequently offered to treat recurrent arrhythmias after an index ablation procedure. Little is known about managing patients with arrhythmia recurrence after initial long-term success (>3 years from index ablation) and whether they still derive quality of life benefit from redo ablation.

40

40

Journal of Cardiovascular Electrophysiology

FEBRUARY 21, 2024

The impact of supraventricular arrhythmias on the outcomes of guideline-compliance implantable cardioverter defibrillators programming. A greater magnitude of reduced ICD therapy was found in those with supraventricular arrhythmias.

Defibrillator 40

Defibrillator Arrhythmia Outcomes Article 40

HeartRhythm

MARCH 31, 2025

Cardiac sympathetic denervation (CSD) is a therapeutic option in patients with refractory ventricular arrhythmias (VAs). However, prospective data on long term outcomes in different population cohorts undergoing CSD are scarce.

40

40

HeartRhythm

MARCH 31, 2025

Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for sleep-disordered breathing (SDB), yet its effects on nocturnal arrhythmia remains underexplored. Arrhythmias particularly atrial fibrillation and SDB are mutually associated, linked to hypoxia, sympathetic activation, and CV instability.

40

40

Nature Reviews - Cardiology

FEBRUARY 27, 2024

Nature Reviews Cardiology, Published online: 28 February 2024; doi:10.1038/s41569-024-01004-2 Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers.

Atrial Fibrillation 107

Atrial Fibrillation Arrhythmia Outcomes 107

Journal of the American Heart Association

FEBRUARY 3, 2025

Cardiac PDE2transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute elevation of PDE2 could be of therapeutic value remains elusive. Journal of the American Heart Association, Ahead of Print. BackgroundPDE2 (phosphodiesterase 2) is upregulated in human heart failure.

Heart Failure 49

Heart Failure Arrhythmia Outcomes 49

DAIC

APRIL 24, 2025

AF, the most common arrhythmia disorder, is becoming more prevalent across the United States, affecting an estimated 10.5 These centers will serve as specialized hubs to improve patient outcomes, streamline care coordination, and enhance the quality of life for those affected by AF. million adults.

52

52